4th Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$947,004
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 19, 2017 $947,004 Replaced
4th Quarter - Amendment Jul 21, 2017 $950,000 Yes

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans-Pacific Partnership (TPP). Transatlantic Trade and Investment Partnership (TTIP). Biologic Exclusivity.

LobbyistCovered position, as disclosed
MICHAEL BRZICA —
KATHRYN LEE ANDERSON CHADWICK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Taxation/Internal Revenue Code TAX

Taxation Issues Related to Opioid Pharmaceuticals.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
HEIDI WILSON —

Contacted: Office of Management & Budget (OMB); SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Inter Partes Review (IPR) process. Patent Settlements.

LobbyistCovered position, as disclosed
MICHAEL BRZICA —
KATHRYN LEE ANDERSON CHADWICK —
CHRISTIAN OMAR CRUZ —
THOMAS JAMES GARRIGAN —
HEIDI WILSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Office of Management & Budget (OMB)

Health Issues HCR

Innovation for Healthier Americans Initiative. H.R.6: 21st Century Cures Act.

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE

Bills named: H.R. 6 (114th)

Medicare/Medicaid MMM

Medicare Part D Program and Generic Drugs. Medicare reimbursement for biosimilars. Medicaid Rebate Penalty. Medicare Part D Low Income Subsidy (LIS) Program. CMMI Part B Drug Demo.

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Office of Management & Budget (OMB)

Budget/Appropriations BUD

FDA Funding. S.2956: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. H.R.5054: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
KATHRYN LEE ANDERSON CHADWICK —
HEIDI WILSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Office of Management & Budget (OMB)

Bills named: S. 2956 (114th), H.R. 5054 (114th)

Pharmacy PHA

Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA) and Generic Drug User Fee Amendments (GDUFA). Labeling of Generic Drugs. Biosimilars Naming. Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products. Prescription Drug Costs. H.R.2841: FAST Generics Act of 2015. H.R.1314: Bipartisan Budget Act of 2015. Risk Evaluation and Mitigation Strategies (REMS). Biologic Exclusivity. Biologics Price Competition and Innovation Act (BPCIA). Pharmaceutical exclusivity. S.3056: CREATES Act of 2016. H.R.6: 21st Century Cures Act.

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE

Bills named: H.R. 1314 (114th), S. 3056 (114th), H.R. 2841 (114th), H.R. 6 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.